First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
Recruiting · NCT07646353 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults | Infections, Mosquito-Borne Diseases, Plasmodium falciparum malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 1 | 2026-10-05 | NCT07646353 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GlaxoSmithKline | 294 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||